von Willebrand factor A domain containing 5AGenealiases: BCSC-1 · BCSC1 · LOH11CR2A
Q-omics provides the consensus-scored VWA5A profile across patient tissues and cancer cell-line models. VWA5A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, VWA5A is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, VWA5A protein abundance shows 27,102 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where VWA5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VWA5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VWA5A survival associations across molecular data types. VWA5A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VWA5A RNA expression–survival associations across cancer types. High VWA5A expression shows unfavorable associations in ESCA and LAML, but favorable associations in UVM, ACC, SKCM and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for VWA5A RNA expression.
This table summarizes VWA5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VWA5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VWA5A shows lower tumor expression in COAD, KIRC, KICH, LUSC, HNSC and READ. The COAD box plot shows higher VWA5A RNA expression in normal versus tumor tissue (log2 FC = −1.635, t-test p < 0.001).
This table shows molecular features associated with VWA5A in patient tissues and cancer cell lines. In patient samples, VWA5A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, VWA5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
